-
October 25, 2012
Zimmer Holdings (ZMH) reported net earnings of $178.1 million or $1.02 per share in the third quarter of 2012 ...
-
October 24, 2012
CR Bard Inc.'s (BCR) third quarter 2012 adjusted earnings of $1.64 per share beat the Zacks Consensus Estimate by a ...
-
October 24, 2012
Amgen (AMGN) continued its strong performance in 2012 with third quarter earnings coming in at $1.66 per share, 23 ...
-
October 23, 2012
3M Company (MMM) announced third-quarter 2012 results before the market opened today, reporting earnings per share ...
-
October 23, 2012
GE may have disappointed, but the company and its stock are both in good shape today.
-
October 22, 2012
Onyx Pharmaceuticals, Inc. (ONXX) recently announced that it has finished enrolling patients for the phase III FOCUS ...
-
October 22, 2012
Symmetry Surgical, a subsidiary of orthopedic implants and instruments maker Symmetry Medical (SMA), recently ...
-
October 19, 2012
Leading medical devices maker C.R. Bard (BCR) is scheduled to report its second quarter fiscal 2012 results after ...
-
October 18, 2012
Imagine if you had bought these stocks 20 years ago.
If you had, then right now you'd be earning dividend yields ...
-
October 17, 2012
J&J is back on a growth track, but the device business needs fixing.
-
October 17, 2012
Better-than expected quarterly results combined with a couple of positive domestic reports guided the benchmarks ...
-
October 17, 2012
Less than impressive earnings results from Intel (INTC), IBM (IBM), and CSX Corp. (CSX) after the close cap a busy ...
-
October 16, 2012
Abbott Laboratories (ABT) recently announced promising data from the phase IIb Aviator trial evaluating the ...
-
October 16, 2012
Johnson & Johnson's (JNJ) third quarter 2012 results exceeded expectations with earnings (excluding special items) ...
-
October 16, 2012
Tuesday, October 16, 2012 With inflation not much of a concern for investors or the Fed, this morning's CPI ...
-
October 16, 2012
Johnson & Johnson (NYSE:JNJ) announced its results for the third quarter on October 16, 2012. Johnson & Johnson is a ...
-
October 11, 2012
We are maintaining our Neutral recommendation on Dendreon Corporation (DNDN) with a target price of $4.75. The stock ...
-
October 11, 2012
Merck (MRK) recently presented encouraging phase IIb data on its type II diabetes candidate, MK-3102, at the annual ...
-
October 11, 2012
When Johnson & Johnson (NYSE:JNJ) releases its third quarter earnings on Tuesday, October 16, 2012, analysts are ...
-
October 10, 2012
Janssen Research & Development, LLC, a part of the Johnson & Johnson (JNJ) family of companies, recently presented ...
